Charlotte Robinson

DocwireNews

Vertex Pharmaceuticals has entered into an agreement to acquire Alpine Immune Sciences, a clinical-stage biotechnology company focused on the discovery and development of protein-based immunotherapies. The transaction is expected to close in the second quarter of 2024.&nbsp;Alpine&rsquo;s lead product is povetacicept, a dual antagonist of BAFF (B-cell activating factor) and APRIL (a proliferation inducing ligand) that has demonstrated potential as a treatment for IgA nephropathy (IgAN). Povetacicept is based on an engineered transmembrane activator and CAML interactor domain and has shown greater binding affinity and potency than other BAFF or APRIL inhibitors. The drug was the subject of the RUBY-3 phase 1b/2a study and is expected to enter phase 3 clinical development later this year.There are no currently approved therapies that target the underlying cause of IgAN, which is the leading cause of primary glomerulonephritis worldwide.&nbsp;Povetacicept is also in development for other autoimmune diseases of the kidney, including nephropathy and lupus nephritis, as well as autoimmune cytopenias.Meanwhile, Vertex is making headway in the treatment of APOL-1 mediated kidney disease (AKMD). Its oral drug candidate inaxaplin, which received Breakthrough Therapy designation from the US Food and Drug Administration in June 2022, will advance to phase 3 of the AMPLITUDE clinical trial. The trial will assess the effects of inaxaplin 45 mg once daily versus placebo on organ function and proteinuria in adults and adolescents aged 10 to 17 years with AKMD.

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Vertex Set to Acquire Alpine, Developer of Promising IgAN Treatment

IgA Nephropathy

Vertex Pharmaceuticals will acquire Alpine Immune Sciences, developer of povetacicept for IgA nephropathy (IgAN).

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe